Management of Diarrhea Induced by Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors

Hirsh, V.; Blais, N.; Burkes, R.; Verma, S.; Croitoru, K.

doi:10.3747/co.21.2241

Open AccessArticle

Management of Diarrhea Induced by Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors

by

V. Hirsh

^1,*,

N. Blais

²,

R. Burkes

³,

S. Verma

⁴ and

K. Croitoru

⁵

¹

Hematology–Oncology Services, Santa Cabrini Hospital, and Department of Oncology, Faculty of Medicine, McGill University, Montreal, QC

²

Department of Medicine, University of Montreal, Montreal, QC

³

Division of Hematology/Medical Oncology, University of Toronto, Mount Sinai Hospital, and The Princess Margaret Hospital Cancer Centre, Toronto, ON

⁴

University of Toronto and Medical Oncology/Hematology, Sunnybrook Health Sciences Centre, Toronto, ON

⁵

University of Toronto, and Division of Gastroenterology, Zane Cohen Centre for Digestive Diseases, Mount Sinai Hospital, Toronto, ON

^*

Author to whom correspondence should be addressed.

Curr. Oncol. 2014, 21(6), 329-336; https://doi.org/10.3747/co.21.2241

Submission received: 3 September 2014 / Revised: 7 October 2014 / Accepted: 12 November 2014 / Published: 1 December 2014

Download

Abstract

Treatment for non-small-cell lung cancer (nsclc) is moving away from traditional chemotherapy toward personalized medicine. The reversible tyrosine kinase inhibitors (tkis) erlotinib and gefitinib were developed to target the epidermal growth factor receptor (egfr). Afatinib, an irreversible ErbB family blocker, was developed to block egfr (ErbB1), human epidermal growth factor receptor 2 (ErbB2), and ErbB4 signalling, and transphosphorylation of ErbB3. All of the foregoing agents are efficacious in treating nsclc, and their adverse event profile is different from that of chemotherapy. Two of the most common adverse events with egfr tkis are rash and diarrhea. Here, we focus on diarrhea. The key to successful management of diarrhea is to treat early and aggressively using patient education, diet, and antidiarrheal medications such as loperamide. We also present strategies for the effective assessment and management of egfr tki–induced diarrhea.

Keywords: non-small-cell lung cancer; epidermal growth factor receptor; tyrosine kinase inhibitors; adverse events; diarrhea management

Share and Cite

MDPI and ACS Style

Hirsh, V.; Blais, N.; Burkes, R.; Verma, S.; Croitoru, K. Management of Diarrhea Induced by Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors. Curr. Oncol. 2014, 21, 329-336. https://doi.org/10.3747/co.21.2241

AMA Style

Hirsh V, Blais N, Burkes R, Verma S, Croitoru K. Management of Diarrhea Induced by Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors. Current Oncology. 2014; 21(6):329-336. https://doi.org/10.3747/co.21.2241

Chicago/Turabian Style

Hirsh, V., N. Blais, R. Burkes, S. Verma, and K. Croitoru. 2014. "Management of Diarrhea Induced by Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors" Current Oncology 21, no. 6: 329-336. https://doi.org/10.3747/co.21.2241

APA Style

Hirsh, V., Blais, N., Burkes, R., Verma, S., & Croitoru, K. (2014). Management of Diarrhea Induced by Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors. Current Oncology, 21(6), 329-336. https://doi.org/10.3747/co.21.2241

Article Menu

Management of Diarrhea Induced by Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors

Abstract

Share and Cite

Article Metrics

Article Access Statistics

Further Information

Guidelines

MDPI Initiatives

Follow MDPI